Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer.
about
Targeted therapies in CLL: mechanisms of resistance and strategies for managementCurrent treatment of early breast cancer: adjuvant and neoadjuvant therapyDiscovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)The phosphoinositide 3-kinase pathway and therapy resistance in cancerRas oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant populationRegulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer.MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.Genomic amplification upregulates estrogen-related receptor alpha and its depletion inhibits oral squamous cell carcinoma tumors in vivoNuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype.ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).Drugging PI3K in cancer: refining targets and therapeutic strategiesUpregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer.Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib.Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.IndividualizedPath: identifying genetic alterations contributing to the dysfunctional pathways in glioblastoma individuals.The prognostic value of PI3K mutational status in breast cancer: a meta-analysis.
P2860
Q27002528-51F02E74-9076-4EB3-8CB8-9ABED4751319Q27011658-352CA99A-8BEE-4F24-B588-10137C34BDAAQ27711042-0072678F-0B55-4396-8069-45B2A7CAF0A1Q28082811-1691DDDE-3E93-4298-92B7-8520742AA279Q33779805-F7A31973-E281-43E9-824D-57225C16BBA1Q33915044-42A0EAB2-0FAD-4B1A-8500-FFBDF4C1E052Q35274741-5E84AB98-7CC1-4714-BE7F-F03BF19B48EAQ36117367-62354D09-8BF1-43A8-A2B1-C03C2321F8DCQ36274292-980F5BD1-BC2B-4C65-B70D-80D6D50EF6A3Q36350201-D097E134-7A5B-49BA-A60B-B5C529831825Q36527994-9A3C5B4C-7032-4643-9DDD-5A2BB85A02FAQ37013898-8C03043A-C11C-4F40-8A27-91BE9E39C62CQ38237619-F44373C1-E09C-45C0-9FBD-9EF16EC4124EQ38385856-8E583C2A-BF7C-4555-B92C-60D34E48F856Q38539217-11A6DC73-19F6-47D4-BB5A-87BBF37F42E0Q38764654-F0972C1E-1191-42D9-8A7C-80D0031CFA99Q38835374-2E761588-6485-4902-AB80-CEA9EB06549EQ39169789-EACDCB5F-C1BE-446E-840F-227D1485011BQ45794856-533042E2-9DFC-44B5-B2B2-D9A317A2F608Q47725954-9ABFDA93-D5A5-4341-B039-4F1F25C6D6F1
P2860
Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Acquired PIK3CA amplification ...... e inhibitors in breast cancer.
@en
Acquired PIK3CA amplification ...... e inhibitors in breast cancer.
@nl
type
label
Acquired PIK3CA amplification ...... e inhibitors in breast cancer.
@en
Acquired PIK3CA amplification ...... e inhibitors in breast cancer.
@nl
prefLabel
Acquired PIK3CA amplification ...... e inhibitors in breast cancer.
@en
Acquired PIK3CA amplification ...... e inhibitors in breast cancer.
@nl
P2093
P2860
P356
P1433
P1476
Acquired PIK3CA amplification ...... e inhibitors in breast cancer.
@en
P2093
G M Hampton
J M Spoerke
M R Lackner
T R Wilson
P2860
P2888
P356
10.1038/ONCSIS.2013.46
P50
P577
2013-12-23T00:00:00Z
P5875
P6179
1018740367